In its Q4 earnings call to investors on February 25, vaccine developer Vaxcyte expressed optimism about its VAX-31 invasive pneumococcal disease (IPD) vaccine program and discussed the company’s ...

Scientific advances have increased the safety and efficacy of recombinant viral-vector technology for cell and gene therapies. In this special report, we will discuss how tailored transfection ...

Cheryl Scott, Editor in Chief When I was supposed to be writing this editorial, I instead was watching the funeral of former US president James Earl Carter of Georgia. The eulogy and speeches by ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

Cheryl Scott, Editor in Chief. BPI is poised to enter its 23rd year in print. The 21st century has brought many changes to publishing(e.g., from online presence as a “value-add” to an essential) but ...

Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

Indian pharmaceutical company Intas Pharmaceuticals signed a deal to acquire Udenyca, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications. Accord ...

The Cydem VT system combines multiple trusted Beckman Coulter Life Sciences technologies into one advanced platform that empowers lab managers with a far more effective, higher-throughput method for ...

This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

Enzyme-linked immunosorbent assays (ELISA) are commonly used in analytical chemistry. They can be used in process development for biologic therapies to detect and quantitate host cell protein (HCP) ...

At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...

Industry will see mid-teens grams/L of product within five years but downstream processes are the big ‘virgin territory’ for further productivity gains, says Avantor’s Ger Brophy. In the aftermath of ...